Lung (includes NSCLC, SCLC, Mesothelioma)

Concurrent Chemotherapy, Proton Therapy Improves Survival In Patients With Advanced Lung Cancer

(MD Anderson) July 20, 2017 - For patients with advanced, inoperable stage 3 lung cancer, concurrent chemotherapy and the specialized radiation treatment, proton therapy, offers improved survival compared to historical data for standard of care, according to a new study from The University of Texas MD Anderson Cancer Center.

read press release

Meeting Highlights From the Committee for Medicinal Products for Human Use (CHMP) 17-20 July 2017

(EMA) July 21, 2017 - Positive recommendations on new medicines included Merck Serono’s Bavencio (avelumab) for the treatment of metastatic Merkel cell carcinoma; Novartis’ Rydapt (midostaurin) for the treatment of acute myeloid leukaemia, aggressive systemic mastocytosis, systemic mastocytosis with associated haematological neoplasm and mast cell leukemia; and Roche’s Tecentriq (atezolizumab) for the treatment of locally advanced or metastatic urothelial carcinoma and of non-small cell lung cancer.

read press release

AstraZeneca CEO Reassures Staff, Aims To Be At September Cancer Meet

(Reuters) July 21, 2017 - AstraZeneca Chief Executive Pascal Soriot, responding to rumors he might leave the drugmaker to join rival Teva Pharmaceutical Industries, has told staff he expects to work together with employees to see the company succeed.

read article

No Dye: Cancer Patients' Gray Hair Darkened On Immune Drugs

(Associated Press) July 21, 2017 - Cancer patients' gray hair unexpectedly turned youthfully dark while taking novel drugs, and it has doctors scratching their heads.

read article

Roche Punts a PhI Cancer Drug Out Of The Pipeline And Back to Oryzon

(Endpoints News) July 20, 2017 - Little Oryzon Genomics in Spain picked up a considerable endorsement and financial support when Roche stepped in three years ago to partner on its lysine specific demethylase-1 (LSD1) inhibitor ORY-1001 (RG6016) for acute myloid leukemia and solid tumors.

read article

A.I. Prizes, Coming to Healthcare, Hit $1M Mark in Cancer Contests

(Xconomy National) July 20, 2017 - Each competition came about because the human radiologist rate of false positives—detection of something that turns out not to be cancer—seems unacceptably high (more than 90 percent for lung scans, and about 50 percent for mammography, according to the National Cancer Institute).

read article

Raising the Dose and Raising the Cost: The Case of Pembrolizumab in Lung Cancer

(JNCI) July 14, 2017 - After adjusting for inflation, the price per life-year gained of cancer drugs rose from $54100 to $207000 over the 20-year time period between 1995 and 2013.

read article

Biothera Pharmaceuticals Announces Initiation of Phase 1b/2 Clinical Study Evaluating Combination of Imprime PGG and Merck’s KEYTRUDA in Non-Small Cell Lung Cancer

(Biothera) July 19, 2017 - Biothera Pharmaceuticals, Inc. today announced that the Big Ten Cancer Research Consortium has begun patient dosing in a Phase 1b/2 clinical study to evaluate Biothera’s Imprime PGG in combination with the Merck anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) in second-line non-small cell lung cancer (NSCLC).

read corporate press release

Cause of Chemoresistance In Small Cell Lung Cancer Discovered

(MedUni Vienna) July 18, 2017 - Approximately one year after successful treatment with cytotoxic chemotherapy and radiotherapy, patients with advanced Small Cell Lung Cancer (SCLC), generally relapse with recurrence of tumours that are resistant to further chemotherapy. Researchers at MedUni Vienna have now discovered a reason why.

read article

The International Association for the Study of Lung Cancer Announces the IASLC 18th World Conference on Lung Cancer

(Yahoo! Finance) July 13, 2017 - The International Association for the Study of Lung Cancer (IASLC) announced today that the IASLC 18th World Conference on Lung Cancer (WCLC) will take place on October 15-18, 2017, in Yokohama, Japan.

read article

Not All Cancer Drug Side Effects Are Unwanted

(Wall Street Journal/MoneyBeat) July 13, 2017 - Sometimes a side effect is more than a side effect.

read article (paid subscription required)

Amgen And Allergan To Discuss Data Supporting Biologics License Application For ABP 215, A Biosimilar Candidate To Avastin® (bevacizumab)

(Morningstar) July 13, 2017 - Amgen and Allergan plc. today announced that the Companies will discuss data supporting the ABP 215 Biologics License Application (BLA) with the Oncologic Drugs Advisory Committee (ODAC) of the U.S. Food and Drug Administration (FDA). ABP 215 is a biosimilar candidate to Avastin® (bevacizumab) and is the first bevacizumab biosimilar candidate to be considered by the FDA.

read article

Association of Community Cancer Centers Begins Testing Phase for Care Coordination Model to Address Disparities Faced by Medicaid Patients with Lung Cancer

(ACCC) July 12, 2017 - The Association of Community Cancer Centers (ACCC) is working to improve care for Medicaid patients with lung cancer through a three-year initiative focused on developing an optimal care coordination model (OCCM) for this population. Funding and support for this project is provided by a grant from the Bristol-Myers Squibb Foundation (BMSF).

read press release

Radiotherapy Dose Increase to PET/CT-Identified Hypoxic NSCLC Lesions Shows Need for New Approaches

(SNMMI) July 10, 2017 — Fluorine-18-fluoromisonidazole (FMISO) is a PET radiotracer that is widely used to diagnose hypoxia (insufficient oxygen supply to tissue), and non-small cell lung cancer (NSCLC) patients with FMISO uptake are known to face a poor prognosis. A multicenter French Phase II study investigated whether a selective radiotherapy dose increase to tumor areas with significant FMISO uptake in NSCLC patients could improve outcomes.

read press release

Novartis Gets Wider EU Approval For Zykadia in Lung Cancer

(Reuters) June 29, 2017 - The European Commission has approved expanding the use of Zykadia (ceritinib) to include the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC) whose tumours are anaplastic lymphoma kinase (ALK)-positive, Swiss drugmaker Novartis said on Thursday.

read article

Fewer U.S. Cancer Survivors Breathing Secondhand Smoke

(Reuters Health) June 28, 2017 - Cancer survivors are less than half as likely to be exposed to secondhand smoke as they were a generation ago, a U.S. study suggests.

read article

Aduro Biotech Announces First Patient Dosed in Phase 2 Clinical Trial of CRS-207 in Combination with KEYTRUDA® (Pembrolizumab) For the Treatment of Patients with Previously Treated Malignant Pleural Mesothelioma

(Morningstar) June 28, 2017 - Aduro Biotech, Inc., a biopharmaceutical company with three distinct immunotherapy technologies, today announced that the first patient has been dosed in the company’s Phase 2 clinical trial in malignant pleural mesothelioma (MPM).

read article

Mystic Study Success Could Put Astra Ahead in Cancer Revolution

(Bloomberg) June 28, 2017 - Test results for AstraZeneca Plc’s next-generation cancer therapy -- among the most anticipated in the pharmaceutical industry this year -- stand to rijig the order of dominance in a field led by Merck & Co.

read article

MabVax Therapeutics Commences Patient Dosing in MVT-1075 Radioimmunotherapy Phase 1 Clinical Trial for the Treatment of Pancreatic, Colon and Lung Cancers

(MabVax Therapeutics) June 27, 2017 - MabVax Therapeutics Holdings, Inc. today announced that the first patient has been dosed in the Phase 1 clinical trial evaluating MVT-1075, the Company's fully human antibody radioimmunotherapy (RIT), for the treatment of CA19-9 positive malignancies including pancreatic, colon and lung cancers.

read corporate press release

Behind Big Pharma's Race To Develop The Next Wave Of Cancer Therapy

(The Telegraph [UK]) June 25, 2017 - Pharmaceutical companies are betting big on a new wave of innovative cancer therapies they believe will be more effective than existing treatments and move them a big step closer to finding a cure for the disease.

read article
Next Page